Working Group on
Defining and Managing Autism Spectrum Disorder


Background and Mission

In 2024, Autism Spectrum Disorder (ASD) is believed to affect one out of every 90 individuals on the planet, across ethnicities and socioeconomic categories. However, due to the scarcity of data from low- and middleincome nations, these figures are likely to be substantially higher. Approximately 2.8% of children in the United States have a diagnosis of autism, a rate that has almost 250% increase in comparison to the beginning of the new century.

ASD is associated with a broad vulnerability to concomitant health issues, especially psychiatric disorders, with a prevalence five or more times higher than in the general population. The identification of concomitant psychiatric disorders in persons with ASD requires a specific knowledge and expertise, since the symptomatology is substantially different from that shown by the general population, especially in persons with low or absent verbal communication skills and illness insight, who express their suffering through changes in behaviour

Around one half of the persons with low-functioning ASD receive psychotropic medication, and in one-third of cases drugs are prescribed to manage problem behaviours such as aggression or self-injury, in the absence of a diagnosed psychiatric disorder.

Despite the evidence on an enormous burden on families and caregivers, the high need of service provision, and the high health and societal costs, ASD is still overlooked as mental health issues by many national and international organizations worldwide, especially in case of substantial and very substantial support need (level 2 and 3), minimal verbal ability and co-occurrence of intellectual disability (including borderline intellectual functioning). Even in those countries where specific care programs are available, significant gaps are usually reported between awareness, planning and delivery of services. Specific training for psychiatrists and other mental health professionals is also often lacking, at every level within the clinical education system, including undergraduate, graduate and postgraduate training as well as professional continuing education. In the academic context of many countries, ASD is still not regarded as an integral part of the mainstream of adult psychiatry.

To address these issues, the WPA has constituted a working group including experts with long-standing contributions to WPA activities in the field.


Aims and actions for the triennium 2024-2026

The WPA Working Group (WG) on Intellectual Disability (ID) has been tasked with the following:

  1. Training materials for the WPA Educational Portal (and or WPA Specialist Corner) on epidemiology, phenomenology, and assessment of psychiatric disorders in persons with ASD, including level 2 and 3 ASD.
  2. Implementation of evidence-based diagnosis and therapies through the WPA Specialist Corner.
  3. Position statement on outcome measures, quality of life, prevention, and preservation of mental health in persons with ASD.
  4. Position statement on the rights to mental health care of persons with ASD (including level 2 and level 3 ASD) and/or other neurodevelopmental disorders, in collaboration with the WPA sections on ‘Stigma and Mental Illness’, ‘Psychiatry of Intellectual and Developmental Disability’, and all the other WPA entities that might be interested in this endeavour.
  5. Survey on the consideration of ASD within adult psychiatry in a sample of countries across the main five continents of the world.
  6. Publications on WPA web and journal of the above-mentioned position statements and survey results.
  7. Participation to the International Working Group of the International Prader-Willi Syndrome Organisation (IPWSO), including the ECHO (Mental Health Extension of Community Healthcare Outcomes) programme.
  8. Participation to the WPA world congresses.
  9. Collaboration with the WPA sections and other WPA entities, especially with the sections on ‘Psychiatry of Intellectual and Developmental Disability’ and on ‘Stigma and Mental Illness, to activities and publications aimed at enhancing policy and practice for neurodevelopmental disorders in psychiatry, along with promoting education and training.
  10. All aims will be pursued in alignment with the WPA EDIT principles

Working Group Members

Deliverables

Within the WPA 2021-2023 Action Plan this group has produced a set of collaborative documents on policies, services, education, and training, in which the issues related to diagnosis, treatment and outcome measures of concomitant psychiatric disorders has occupied a central place. The provision of strategies for interdisciplinary approaches and the promotion of partnerships for joint collaborative work in capacity building among medical students, young psychiatrists and allied professionals have represented other main focuses. A description of the main activities is provided below: